Latest profit margin for Gemina Laboratories: -10354.68% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jan 2026
Trailing 12 months ending Jan 2026
The latest profit margin for GLAB.CN is -10354.68% as of January 2026. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Gemina Laboratories's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, GLAB.CN currently prints -10354.68% for profit margin, while the sector average sits near 9.48%. That is roughly 109315.5% below the sector mean. Large gaps often invite a closer look at Gemina Laboratories's growth, margins, and balance sheet.
Profit Margin shows how effectively Gemina Laboratories converts resources into returns. At -10354.68%, GLAB.CN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GLAB.CN's profit margin (-10354.68%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Gemina Laboratories's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.